Premium
ChlVPP/ABVVP, a first line ‘hybrid’ combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis
Author(s) -
Martinelli G.,
Cocorocchio E.,
Peccatori F.,
Zucca E.,
Saletti P. C.,
Calabrese L.,
Pastano R.,
Pruneri G.,
Mazzetta C.,
Ghielmini M.,
Cavalli F.
Publication year - 2004
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2004.04962.x
Subject(s) - procarbazine , medicine , vincristine , abvd , dacarbazine , vinblastine , gastroenterology , surgery , etoposide , chlorambucil , chemotherapy , oncology , cyclophosphamide
Summary We retrospectively analysed toxicities and clinical results of 61 Hodgkin's lymphoma patients treated with chlorambucil, vinblastine, procarbazine, doxorubicin, bleomycin, vincristine and etoposide (ChlVPP/ABVVP), delivered in a weekly alternate schedule. Of 61 patients, 33 were in stages III–IV, 21 in stage IIB and seven in stage IIA with bulky disease or extranodal presentation. ChlVPP/ABVVP was administered for 6–8 cycles. Involved field radiotherapy (IFRT) (30–35 Gy) was delivered to 31 patients with residual disease after chemotherapy or bulky disease at diagnosis. Of 61 patients, 58 (95%) achieved complete clinical or radiological remission after chemotherapy and IFRT. With a median follow‐up of 60 months, 5‐year overall survival, relapse‐ and event‐free survival were 78·8% (95% CI 68·2–91·1%), 81% (95% CI 70·6–92·2%) and 71·9% (95% CI 68·2–82·2%) respectively. Grades 3–4 neutropenia was the most relevant haematological toxicity and occurred in 82% of patients. Non‐haematological toxicities were mild and reversible. No toxic deaths were recorded. One patient developed secondary acute myeloid leukaemia 1 year after ChlVPP/ABVVP. Due to the retrospective nature of this study, no definitive conclusions could be drawn about the clinical activity of ChlVPP/ABVVP. Nonetheless, clinical results seem better than those reported with standard regimens [ABVD (doxorubicin, bleomycin, vincristine, dacarbazine), MOPP (methotrexate, vincristine, procarbazine, prednisone), MOPP/ABVD] and as good as those reported using standard or escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone), with a lower degree of haematological and non‐haematological toxicity. Long‐term results of the ongoing randomized trial, comparing ABVD versus high‐dose intensity weekly regimens will be useful to confirm our results.